- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04527302
Efficacy of Augmentation of Cognitive Behavioral Therapy With Transcranial Direct Current Stimulation for Obsessive-Compulsive Disorder (OCD)
A Randomized Clinical Trial of Transcranial Direct Current Stimulation (tDCS) Concurrent With Exposure-based Cognitive-Behavioral Therapy (CBT) for Obsessive-Compulsive Disorder (OCD)
Study Overview
Status
Conditions
Detailed Description
The current study aims to evaluate feasibility and clinical outcome of exposure-based CBT(ERP)combined with tDCS over the prefrontal cortex (mPFC) in treatment of OCD patients. 60 OCD patients whose symptom were mainly associated with "contamination/clean" will be randomized into two groups (i.e. ERP+active tDCS or ERP+sham tDCS stimulation). Over a two-month period, all patients are received 10 sessions of individual CBT, including 8 sessions of concurrent tDCS with ERP (tDCS+ERP). Three independent evaluators will rate the severity of patients' obsessive-compulsive symptoms using Y-BOCS at four assessment points: baseline (prior to the treatment), after the first (session 2#), fourth (session 5#), and eighth treatment of tDCS+ERP (session 10#). The patients will also receive MRI scan and EEG.
The current study aims to explore whether the administration of online tDCS together with ERP (tDCS+ERP) will improve the efficacy of ERP and tries to provide some early evidience that reveal potential neural mechanisms of the treatment.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zhen Wang, PhD,MD
- Phone Number: +86 34773516
- Email: wangzhen@smhc.org.cn
Study Contact Backup
- Name: Zhen Wang, PhD,MD
- Phone Number: +86 64387250
- Email: wangzhen@smhc.org.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Shanghai Mental Health Center
-
Contact:
- Zhen Wang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
We recruited outpatient adults with OCD confirmed by the Mini-International Neuropsychiatric Interview (MINI). The following inclusion and exclusion criteria were also applied:
Inclusion Criteria:
(1) 18-50 years old, with at least 9 years of education, (2) Y-BOCS score ≥16, (3) no history of serious medical, neurological illness or other psychotic disorders other than OCD (anxiety or mild to moderate depression secondary to OCD was not exclusionary), (4) medication-free or had received stable medication for at least 2 months before entering the study and continued the same medication throughout the study (5) no previous exposure to ERP or tDCS.
Exclusion Criteria:
- history of serious medical, neurological illness or other psychotic disorders other than OCD
- The inability to receive tDCS because of metallic implants, or history of seizures,or history of head injury, or history of neurosurgery.
- Participants who have received ECT, rTMS, tDCS and CBT in the past.
- Participants with claustrophobic, heart pacemaker, mechanical heart valve, mechanical implant such as an aneurysm clip, hip replacement, or any other pieces of metal that have accidentally entered their body.
- serious suicide risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: active tDCS+exposure based CBT
The exposure and response prevention (ERP) treatment concurrently with an anode transcranial direct current stimulation over the mPFC will be applied 8 times (tDCS+ERP, 8sessions) in the whole treatment.
|
The active tDCS +ERP referred to a period of tDCS applied in the first 20 minutes of the ERP treatment (the tDCS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tDCS+ERP treatment. The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Anode electrode will be localized in front of the mPFC on the FpZ point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AF7, AF8, F3, F4). |
Sham Comparator: sham tDCS +exposure based CBT
the exposure and response prevention (ERP) treatment concurrently with an sham transcranial direct current stimulation over the mPFC will be applied 8 times (sham tDCS+ERP, 8 sessions) in the whole treatment.
|
Patients will get the same CBT setting as the active tDCS group and they were applied the sham tDCS cocurrently with ERP.
The sham tDCS device is the same as the active comparator's except that the sham tDCS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tDCS.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary outcome was represented by the percent reduction of Y-BOCS scores
Time Frame: baseline,2 weeks,4 weeks to 8 weeks (pre-treatment, after Session 2, 5, 10)
|
We defined the tDCS+ERP treatment response as the percent reduction of Y-BOCS scores greater than or equal to 35%.
|
baseline,2 weeks,4 weeks to 8 weeks (pre-treatment, after Session 2, 5, 10)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Obsessive Compulsive Inventory-Revised(OCI-R)
Time Frame: baseline,2 weeks,4 weeks to 8 weeks(pre-treatment, after Session 2, 5, 10)
|
It is an inventory of OCD symptoms with 18 items that are rated on a 5-point Likert scale.
Total scores range from 0 to 72, with higher scores indicating more severe OCD symptoms.
|
baseline,2 weeks,4 weeks to 8 weeks(pre-treatment, after Session 2, 5, 10)
|
Change in Beck Depression Inventory(BDI)
Time Frame: baseline,2 weeks,4 weeks to 8 weeks(pre-treatment, after Session 2, 5, 10)
|
It consists of 21 items and uses a 0 to 3 severity scale.
Total scores range from 0 to 63, with higher scores indicating more severe depression symptoms.
|
baseline,2 weeks,4 weeks to 8 weeks(pre-treatment, after Session 2, 5, 10)
|
Change in Beck Anxiety Inventory (BAI)
Time Frame: baseline,2 weeks,4 weeks to 8 weeks(pre-treatment, after Session 2, 5, 10)
|
It is an inventory of anxiety symptoms with 18 items that are rated on a 5-point Likert scale(0 to 4).
Total scores range from 0 to 72, with higher scores indicating more severe anxiety symptoms.
|
baseline,2 weeks,4 weeks to 8 weeks(pre-treatment, after Session 2, 5, 10)
|
Change in Perceived Stress Scale(PSS)
Time Frame: baseline,2 weeks,4 weeks to 8 weeks(pre-treatment, after Session 2, 5, 10)
|
It is a 10-item, 5-point Likert scale(0 to 4) to measure the degree to which situations in one's life are appraised as stressful.The total score ranges from 0 to 40, with lower total scores representing a better outcome.
|
baseline,2 weeks,4 weeks to 8 weeks(pre-treatment, after Session 2, 5, 10)
|
Change in Pittsburgh sleep quality index(PSQI)
Time Frame: baseline,2 weeks,4 weeks to 8 weeks(pre-treatment, after Session 2, 5, 10)
|
The Pittsburgh Sleep Quality Index (PSQI) contains 19 self-rated questions which measures seven aspects of sleep: (1) subjective sleep quality, (2) sleep latency, (3) sleep duration, (4) habitual sleep efficiency, (5) sleep disturbances, (6) use of sleeping medication, and (7) daytime dysfunction.
The 19 self-rated items are combined to form seven component scores, each of which has a range of 0-3 points (0 indicates no difficulty, while 3 indicates severe difficulty).
The seven component scores are then summed to yield one global score, with a range of 0-21 points (0 indicating no difficulty, and 21 indicating severe difficulties in all the seven areas of sleep quality).
|
baseline,2 weeks,4 weeks to 8 weeks(pre-treatment, after Session 2, 5, 10)
|
Change in Side-effect questionnaire
Time Frame: 2 weeks,4 weeks to 8 weeks(after Session 2, 5, 10)
|
It consists of 10-item and uses 0 to 3 severity scale to rate the intensity of side effects.
Total scores range from 0 to 30, with higher scores indicating more severe side-effect.
It also assesses the relation between side-effect and the effects of tDCS using 0 to 4 scale.
Total scores range from 0 to 40, with higher score indicating the greater relation.
|
2 weeks,4 weeks to 8 weeks(after Session 2, 5, 10)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zhen Wang, PhD,MD, Shanghai Mental Health Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMHC-OCD-008
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Chaim HuijserLevvelRecruitingObsessive-Compulsive Disorder | Anxiety Disorders and Symptoms | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceNetherlands
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
Roseli ShavittCompleted
Clinical Trials on ERP combined with high-definition active tDCS
-
University of TehranRecruitingHealthy VolunteersIran, Islamic Republic of
-
Hôpital le VinatierRecruiting
-
Hôpital le VinatierNot yet recruiting
-
University of New MexicoUniversity of Miami; The City College of New York; The Mind Research Network; New... and other collaboratorsCompletedMild Traumatic Brain InjuryUnited States
-
Monash UniversityZonMw: The Netherlands Organisation for Health Research and Development; Erasmus...Completed
-
Tianjin Anding HospitalChinese Academy of SciencesEnrolling by invitationSchizophrenia Negative TypeChina
-
Kessler FoundationRecruitingTraumatic Brain Injury | Upper Extremity DysfunctionUnited States
-
Assistance Publique - Hôpitaux de ParisSorbonne University; Université de Technologie de CompiegneCompleted
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RecruitingPrimary Progressive Aphasia | Logopenic Progressive AphasiaUnited States